Toripalimab

Generic Name
Toripalimab
Brand Names
Loqtorzi
Drug Type
Biotech
Chemical Formula
-
CAS Number
1924598-82-2
Unique Ingredient Identifier
8JXN261VVA
Background

Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).

Indication

⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

First Posted Date
2024-04-09
Last Posted Date
2024-04-11
Lead Sponsor
Fudan University
Target Recruit Count
20
Registration Number
NCT06354231
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

First Posted Date
2024-03-27
Last Posted Date
2024-10-15
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
300
Registration Number
NCT06333561
Locations
🇨🇳

Chinese PLA General hospital, Beijing, Beijing, China

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

First Posted Date
2024-03-21
Last Posted Date
2024-08-20
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
148
Registration Number
NCT06323239
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

First Posted Date
2024-03-21
Last Posted Date
2024-03-21
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
240
Registration Number
NCT06323382
Locations
🇨🇳

Chinese PLA hospital, Beijing, Beijing, China

Toripalimab Combined With SBRT for NSCLC

Phase 2
Not yet recruiting
Conditions
Non-small Lung Cancer
Interventions
Drug: Toripalimab
First Posted Date
2024-03-05
Last Posted Date
2024-03-06
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
40
Registration Number
NCT06293690
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

First Posted Date
2024-02-28
Last Posted Date
2024-02-28
Lead Sponsor
RenJi Hospital
Target Recruit Count
20
Registration Number
NCT06279403

A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

First Posted Date
2024-02-28
Last Posted Date
2024-02-29
Lead Sponsor
China Medical University, China
Target Recruit Count
8
Registration Number
NCT06283303

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

First Posted Date
2024-02-28
Last Posted Date
2024-02-29
Lead Sponsor
China Medical University, China
Target Recruit Count
30
Registration Number
NCT06283121

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

First Posted Date
2024-02-28
Last Posted Date
2024-02-29
Lead Sponsor
China Medical University, China
Target Recruit Count
40
Registration Number
NCT06283134

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

Phase 2
Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Toripalimab
First Posted Date
2024-02-21
Last Posted Date
2024-11-18
Lead Sponsor
Ruijin Hospital
Target Recruit Count
29
Registration Number
NCT06269211
Locations
🇨🇳

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy